Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Atreca, Inc. (BCEL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update SAN CARLOS, Calif., Nov. 10, 2022 -- SAN CARLOS, Calif., November 10, 2022 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101,” said John Orwin, Chief Executive Officer of Atreca. “We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observe..." |
|
| 08/08/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 04/05/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events Interactive Data |
| 03/03/2022 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., Nov. 02, 2021 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments. "In the third quarter, we continued to advance our lead program, ATRC-101, following the release of initial summary data from the dose escalation portion of the Phase 1b trial, which supports the further evaluation of ATRC-101 in multiple solid tumor types,” said John Orwin, Chief Executive Officer. “We plan to share additional monotherapy dat..." |
|
| 10/21/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2021 |
8-K
| Quarterly results |
| 07/29/2021 |
8-K
| Quarterly results |
| 07/20/2021 |
8-K
| Quarterly results |
| 07/19/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/15/2021 |
8-K
| Quarterly results |
| 05/13/2021 |
8-K
| Quarterly results |
| 03/31/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments. “We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021,” said John Orwin, Chief Executive Officer. “We recently presented preclinical data at SITC 2020 further highlighting the potent..." |
|
| 08/12/2020 |
8-K
| Quarterly results |
| 07/16/2020 |
8-K
| Quarterly results |
| 07/08/2020 |
8-K
| Entry into a Material Definitive Agreement |
| 06/16/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/21/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/14/2020 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments SOUTH SAN FRANCISCO, Calif., May 14, 2020 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2020, and provided an overview of recent developments. “While the COVID-19 pandemic has presented unexpected challenges, we continue to execute on our pipeline and business strategy, and we look forward to further progress throughout 2020,” said John Orwin, Chief Executive Officer. “Patients continue to be enrolled and treated in our Phase 1b dose-escalation clinical trial evaluating ATRC-101 ..." |
|
| 03/11/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/22/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/13/2019 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif.— — August 13, 2019 — Atreca, Inc. , a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the second quarter ended June 30, 2019, and provided an overview of Atreca's recent developments. “The second quarter of 2019 was a highly productive period for Atreca, highlighted by the completion of our successful initial public offering, which further strengthens our ability to execute on the promise of our differentiated technology platform drawn from a deep understanding of the human immune response,” said John Orwin, Chief Executive Officer. “We believe our lead product candidate, ..." |
|
| 07/23/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 06/26/2019 |
8-K
| Quarterly results |
|
|